Overview
- 4 inspections across 4 sites are on record.
- 0 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2024-02-02.
At a glance
Inspections
4
Sites
4
Observations
0
Career since
Oct 2020
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| Lonza Houston, Inc | 2 Feb 2024 | Biologics | |
| Carsgen Therapeutics Corporation | 6 Dec 2023 | Biologics | On file |
| Bristol-Myers Squibb Company | 5 May 2023 | Biologics | On file |
| Juno Therapeutics, Inc. | 16 Oct 2020 | Biologics | On file |
Sites inspected
Lonza Houston, IncHouston, United States1 insp.
Carsgen Therapeutics CorporationDurham, United States1 insp.
Bristol-Myers Squibb CompanyDevens, United States1 insp.
Juno Therapeutics, Inc.Bothell, United States1 insp.
Co-investigators
Investigators who share inspections with this person.
Rabia Ballica2 shared
Kimberly L Schultz2 shared
Pankaj K Mandal1 shared
Phillip C Thai1 shared
Viviana R Ramirez1 shared
Graeme E Price1 shared
Latorie S Jones1 shared
Zhongren Wu1 shared
Travis S Bradley1 shared
David E Bailey1 shared
Full investigator report
Get the verbatim findings behind Nirjal Bhattarai's inspection record
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site